These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 30428474)

  • 1. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
    Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
    Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
    Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
    Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial.
    Wang JY; Bajaj JS; Wang JB; Shang J; Zhou XM; Guo XL; Zhu X; Meng LN; Jiang HX; Mi YQ; Xu JM; Yang JH; Wang BS; Zhang NP
    J Dig Dis; 2019 Oct; 20(10):547-556. PubMed ID: 31448533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
    Saboo K; Shamsaddini A; Iyer MV; Hu C; Fagan A; Gavis EA; White MB; Fuchs M; Heuman DM; Sikaroodi M; Iyer RK; Gillevet PM; Bajaj JS
    J Hepatol; 2021 Jan; 74(1):80-88. PubMed ID: 32679299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
    Bajaj JS
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota.
    Wang MW; Ma WJ; Wang Y; Ma XH; Xue YF; Guan J; Chen X
    Front Microbiol; 2023; 14():1091167. PubMed ID: 37032856
    [TBL] [Abstract][Full Text] [Related]  

  • 9.  Minimal hepatic encephalopathy in cirrhosis- how long to treat?
    Goyal O; Sidhu SS; Kishore H
    Ann Hepatol; 2017 Jan-Feb 2017; 16(1):115-122. PubMed ID: 28051800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linkage of gut microbiome with cognition in hepatic encephalopathy.
    Bajaj JS; Ridlon JM; Hylemon PB; Thacker LR; Heuman DM; Smith S; Sikaroodi M; Gillevet PM
    Am J Physiol Gastrointest Liver Physiol; 2012 Jan; 302(1):G168-75. PubMed ID: 21940902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.
    Hudson M; Schuchmann M
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):434-450. PubMed ID: 30444745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hepatic encephalopathy in the hospital.
    Leise MD; Poterucha JJ; Kamath PS; Kim WR
    Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
    Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
    Bajaj JS; Sikaroodi M; Shamsaddini A; Henseler Z; Santiago-Rodriguez T; Acharya C; Fagan A; Hylemon PB; Fuchs M; Gavis E; Ward T; Knights D; Gillevet PM
    Gut; 2021 Jun; 70(6):1162-1173. PubMed ID: 32998876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
    Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
    Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
    Kang SH; Lee YB; Lee JH; Nam JY; Chang Y; Cho H; Yoo JJ; Cho YY; Cho EJ; Yu SJ; Kim MY; Kim YJ; Baik SK; Yoon JH
    Aliment Pharmacol Ther; 2017 Nov; 46(9):845-855. PubMed ID: 28836723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifaximin in the treatment of chronic hepatic encephalopathy.
    Puxeddu A; Quartini M; Massimetti A; Ferrieri A
    Curr Med Res Opin; 1995; 13(5):274-81. PubMed ID: 7555036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
    Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
    J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.